AW
CDTX

Avion Wealth’s Cidara Therapeutics CDTX Stock Holding History

Avion Wealth’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250
Closed -$23K – 1275
2025
Q3 		$23K Hold
250
– – ﹤0.01% 314
2025
Q2 		$12K Hold
250
– – ﹤0.01% 414
2025
Q1 		$6K Hold
250
– – ﹤0.01% 490
2024
Q4 		$6K Hold
250
– – ﹤0.01% 489
2024
Q3 		$2K Buy
+250
New +$3K ﹤0.01% 661

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Avion Wealth's CDTX Position: Q4 2025 in Review

Avion Wealth sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 250 shares — an estimated $23K sold.

Avion Wealth first reported a position in CDTX in Q3 2024 and held it in 5 quarters. The position peaked at $23K in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Avion Wealth reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Avion Wealth sold 250 Cidara Therapeutics shares in Q4 2025, an estimated $23K.
  • Avion Wealth first reported a position in Cidara Therapeutics in Q3 2024 and held it in 5 quarters.
  • Avion Wealth's Cidara Therapeutics position peaked at $23K in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Avion Wealth's 13F filing for Q4 2025, filed 23 Jan 2026.